Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
25%(2 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
1
10%
Ph early_phase_1
1
10%
Ph phase_1
8
80%

Phase Distribution

9

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
8(80.0%)
Phase 2Efficacy & side effects
1(10.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
88.9%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (10.0%)
Phase 18 (80.0%)
Phase 21 (10.0%)

Trials by Status

completed880%
withdrawn110%
terminated110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

NCT00194714
completedphase_1

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

NCT01355393
completedphase_1

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

NCT00003002
completedearly_phase_1

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

NCT00640861
completedphase_1

Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

NCT01632332
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00194714Phase 1

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

Completed
NCT01355393Phase 1

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

Completed
NCT00003002Phase 1

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

Completed
NCT00640861Early Phase 1

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Completed
NCT01632332Phase 1

Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

Completed
NCT00005023Phase 1

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

Completed
NCT00791037Phase 1

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

Completed
NCT01729884Phase 2

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

Terminated
NCT00068614Phase 1

HER-2 Protein Vaccine in Treating Women With Breast Cancer

Completed
NCT01219907Phase 1

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10